A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study Of Pembrolizumab (MK-3475) With Or Without Lenvatinib (E7080/MK-7902) To Evaluate The Safety And Efficacy Of Pembrolizumab And Lenvatinib As 1L Intervention In A PD-L1 Selected Population Of Participants With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) Read more
Observational Study Of Fostamatinib As Second Line Therapy In Adult Patients With Immune Thrombocytopenia (ITP) And Insufficient Response To A Prior Therapy Read more
Phase III Randomized Study Of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy And Consolidation Therapy In Actively Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia Read more
An Open-Label, Randomized Phase 3 Study Of MK-6482 Versus Everolimus In Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 And VEGF-Targeted Therapies Read more
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Of Infigratinib For The Adjuvant Treatment Of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302) Read more
A Phase Ib/Ii,Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-Tnbc) Read more
A Prospective Multi-Site Single- Arm Phase II Study To Investigate Breast IORT – The Efficacy Of Single-Fraction Intraoperative Radiation Treatment Using A Multi-Lumen Balloon Applicator And In-Room CT Imaging For The Treatment Of Early-Stage Breast Cancer. Read more
OXEL: A Pilot Study Of Immune Checkpoint Or Capecitabine Or Combination Therapy As Adjuvant Therapy For Triple Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy Read more
